1. Clinical & Scientific Overview
Teicoplanin (TIP-MED-000338, Reference Code [8.27]-C68) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICMR 'Reserve' Group (Schedule H | NLEM 2022 | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [8.27] (Vancomycin & Teicoplanin (Glycopeptide Reserve Antibiotics)). Representative Indian Market Examples (Edition 2.7 Ch 08 [8.27], p. 106): Vancomycin: Vancocin CP (AstraZeneca), Vancoled, Forstaf. Teicoplanin: Targocid (Sanofi), Ticocin (Cipla), Teicocarb — Strengths & Dosage Forms: Vancomycin Lyophilised Vials: 500 mg, 1000 mg (1 g) for IV infusion (or oral reconstitution for C. difficile!). Teicoplanin Vials: 200 mg, 400 mg for IV/IM
Vancomycin Lyophilised Vials: 500 mg, 1000 mg (1 g) for IV infusion (or oral reconstitution for C. difficile!). Teicoplanin Vials: 200 mg, 400 mg for IV/IM
3. Mechanism of Action & Pharmacodynamics
Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICMR 'Reserve' Group (Schedule H | NLEM 2022 | HIGH-ALERT) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICMR 'Reserve' Group (Schedule H | NLEM 2022 | HIGH-ALERT) for Severe invasive MRSA infections (bacteraemia, endocarditis, osteomyelitis, HAP/VAP, meningitis), ampicillin-resistant Enterococcal infections, and severe beta-lactam allergy. ORAL Vancomycin (125 mg PO QID) is first-line for Clostridioides difficile colitis!.
4. Therapeutic Indications & Evidence-Supported Uses
- Severe invasive MRSA infections (bacteraemia, endocarditis, osteomyelitis, HAP/VAP, meningitis), ampicillin-resistant Enterococcal infections, and severe beta-lactam allergy
- ORAL Vancomycin (125 mg PO QID) is first-line for Clostridioides difficile colitis!
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Vancomycin IV: Load 20–25 mg/kg IV, then 15–20 mg/kg IV q8–12h guided by TDM (Target trough 10–20 mcg/mL). Vancomycin ORAL (for C. difficile ONLY!): 125 mg PO QID x 10 days. Teicoplanin IV/IM: Load 6–12 mg/kg q12h x 3 doses, then 6–12 mg/kg ONCE DAILY
Administration & Meal Timing: CRITICAL INFUSION RATE RULE FOR VANCOMYCIN: Dilute 500 mg in >=100 mL (1000 mg in >=200 mL) of NS/D5W and infuse SLOWLY at <=10 mg/minute (minimum 60 min for 500 mg; 90–120 min for 1000 mg!) to prevent 'Red Man Syndrome'! | Vancomycin IV: q8–12h (adjusted by CrCl). Teicoplanin: Once Daily (after 3 loading doses). Oral Vancomycin: QID
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [8.27].
Renal: >90% excreted unchanged by glomerular filtration — mandatory dose/interval adjustment by CrCl and TDM trough monitoring in all CKD patients!
Renal: >90% excreted unchanged by glomerular filtration — mandatory dose/interval adjustment by CrCl and TDM trough monitoring in all CKD patients!
Renal: >90% excreted unchanged by glomerular filtration — mandatory dose/interval adjustment by CrCl and TDM trough monitoring in all CKD patients!
7. Contraindications, Precautions & High-Risk Warnings
- ROUTE CONFUSION HAZARD: IV Vancomycin does NOT cross the gut mucosa to treat C. difficile colitis, and Oral Vancomycin is NOT absorbed (<1%) and NEVER treats systemic MRSA infections! Contraindicated in prior glycopeptide SJS/DRESS/anaphylaxis
Key Clinical Precautions: Renal: >90% excreted unchanged by glomerular filtration — mandatory dose/interval adjustment by CrCl and TDM trough monitoring in all CKD patients!
8. Adverse Effects Profile
- Vancomycin Infusion Reaction ('Red Man Syndrome' — erythematous flushing of face/neck/upper torso, pruritus, & hypotension from rapid infusion — slow infusion to >=2 hours and pre-medicate with antihistamine!), phlebitis
- Acute Kidney Injury / Nephrotoxicity (risk rises sharply if trough >20 mcg/mL or combined with Piperacillin-Tazobactam or Aminoglycosides!), Ototoxicity, severe thrombocytopenia, DRESS syndrome
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Piperacillin-Tazobactam + Vancomycin = 2–3x higher AKI risk!; Aminoglycosides (Amikacin/Gentamicin), Amphotericin B, Loop diuretics, and NSAIDs = additive nephrotoxicity & ototoxicity; potentiates anaesthetic neuromuscular blockers
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [8.27].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Ensure nurses infuse Vancomycin 1 g over at least 90–120 minutes (never faster!); check daily creatinine and trough levels; verify whether Vancomycin is ordered IV (for MRSA) or Orally (for C. difficile diarrhoea)
- Meal & Clock Timing Instruction: CRITICAL INFUSION RATE RULE FOR VANCOMYCIN: Dilute 500 mg in >=100 mL (1000 mg in >=200 mL) of NS/D5W and infuse SLOWLY at <=10 mg/minute (minimum 60 min for 500 mg; 90–120 min for 1000 mg!) to prevent 'Red Man Syndrome'! (Vancomycin IV: q8–12h (adjusted by CrCl). Teicoplanin: Once Daily (after 3 loading doses). Oral Vancomycin: QID)
- Missed Dose Protocol: Hospital scheduled dosing
- Geriatric Dispensing Pearl: Always calculate Cockcroft–Gault CrCl and monitor Vancomycin troughs closely in older adults
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Vancomycin Lyophilised Vials: 500 mg, 1000 mg (1 g) for IV infusion (or oral reconstitution for C. difficile!). Teicoplanin Vials: 200 mg, 400 mg for IV/IM
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.8]-CMP54 Norfloxacin IP — Second-Generation Fluoroquinolone Antibiotic (Bactericidal DNA Gy
- [8.11]-CMP55 Ornidazole & Tinidazole IP — 5-Nitroimidazole Antiprotozoal & Anaerobic Bactericidal Antibioti
- [8.15]-C57 Cloxacillin — Aminopenicillin, Isoxazolyl Penicillin & Long-Acting Depot Penici
- [8.15]-C58 Benzathine Penicillin G — Aminopenicillin, Isoxazolyl Penicillin & Long-Acting Depot Penici
